Product Images Valsartan And Hydrochlorothiazide

This is a table showing the effect of Valsartan-HCTZ and Valsartan alone on systolic blood pressure (SBP) in patients with hypertension. The baseline SBP ranges from 140 to 180 mmHg, and the treatments are compared against placebo. The goal of the treatment is to reduce SBP to below 140 mmHg.*

This is a table with blood pressure measurements in mmHg for different treatments. The DBP (diastolic blood pressure) target is below 90mmHg. The treatments include Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo. The baseline DBP measurement is 105 mmHg.*

This text is displaying blood pressure readings before and after treatment. The first line suggests that the target systolic blood pressure is less than 130 mmHg. The next lines display various blood pressure readings ranging from 140 to 180 mmHg. The next few lines indicate three treatment options: Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, and Placebo. Finally, the last line shows the baseline SBP (mmHg), which is the initial blood pressure reading before the treatment.*

This is a tabular representation of blood pressure levels of patients in a study who were administered with Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg and Placebo. The systolic blood pressure of patients at baseline was not available.*

This is a medication package of Valsartan Hctz, which is a combination of two drugs used to lower high blood pressure, represented by purple capsule-shaped tablets with the inscription O 349HH and 320/25mg strength. The medication is produced by Zhejiang Huahai Pharma Co., Ltd and should be stored at temperatures between 20°-25°C (68°-77°F). The medication is to be kept out of the reach of children. The package contains 30 tablets and the expiration date is not explicitly stated.*